Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Exp Toxicol Pathol ; 65(5): 689-94, 2013 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-23083629

RESUMEN

Parkinson's disease (PD) is recognized as the second most common neurodegenerative disorder after Alzheimer's disease. PD is mainly characterized by a selective degeneration of the dopaminergic neurons in the substantia nigra. Also, it is observed imbalances in some nondopaminergic systems, including the serotonergic system. Serotonergic dysfunction appears to play a role in some parkinsonian symptoms, including motor function, L-dopa-induced dyskinesia, mood, psychosis, and constipation. The fact that 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) causes a parkinsonian syndrome was discovered in 1982 and has been used extensively and successfully in various mammalian species, including monkeys and mice, to produce an experimental model of PD. Three common dosing regimens of the MPTP-induced mice model of PD were compared on dopaminergic neurotransmission and serotonin levels in various brain regions. Results showed that tyrosine hydroxylase activity and dopaminergic transporter density were reduced in striatum and substantia nigra of mice and that this reduction was dependent on the cumulative dose of MPTP injected. Furthermore, for the three protocols, a decrease of dopamine (DA) level was observed in striatum, associated with a significant diminution of DA concentration in frontal cortex only for the chronic treatment. Moreover, a decrease of serotonin level was observed in midbrain and hippocampus of acute and sub-acute intoxicated-mice. In all, the results suggested that dosing regimen should be carefully pre-considered. Furthermore, the acute and sub-acute MPTP protocols represent good models of early, subclinical stages of PD, ideal in the development of neuroprotective strategies.


Asunto(s)
1-Metil-4-fenil-1,2,3,6-Tetrahidropiridina , Encéfalo/efectos de los fármacos , Modelos Animales de Enfermedad , Trastornos Parkinsonianos/inducido químicamente , Transmisión Sináptica/efectos de los fármacos , Animales , Encéfalo/metabolismo , Encéfalo/fisiopatología , Dopamina/metabolismo , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática/metabolismo , Inmunohistoquímica , Masculino , Ratones , Ratones Endogámicos C57BL , Trastornos Parkinsonianos/fisiopatología , Serotonina/metabolismo , Tirosina 3-Monooxigenasa/metabolismo
2.
BMJ Case Rep ; 20092009.
Artículo en Inglés | MEDLINE | ID: mdl-21686553

RESUMEN

Neurological syndromes secondary to acute aortic dissection (AAD) are uncommon and usually consist of focal deficits after an embolic cerebral infarction. This article reports the observation of an AAD with the chief complaint of transient acute memory impairment-that is, a non-usual stroke-like symptom.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA